Author Archives: Barbara Arzymanow

About Barbara Arzymanow

Barbara Arzymanow is a Research Fellow at 2020health and is a founding director of an independent healthcare consultancy firm. She has been an investment analyst specialising in Pharmaceuticals for 25 years, prior to which she carried out academic medical research in university laboratories. Her experience, obtained entirely from outside the pharmaceutical industry, gives her a unique, political perspective independent of commercial lobbies. She has extensive experience in financing the biotechnology industry, which is vital for the long-term standing of medical research in the UK. She has always been inspired by the scientific excellence within the UK and would like to see collaborations between industry, the NHS and academia strengthened. For more information about Barbara's research and writings including submissions to Government Departments please visit http://www.researchideas.co.uk . Barbara also tweets as @barbararesearch .

Pharmaceutical Industry- Innovation is the only way forward.

The headline news from the Health and Social Care Information Centre (HSCIC) states that more than 1 billion prescription items were dispensed by community pharmacies in England for the first time in 2012. However, we must not be complacent about the serious … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , | 1 Comment

Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing

Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading

Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing | Tagged , , , , , , , , , , , , | 1 Comment

Guest Blogspot: Prevention is better than cure.

The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading

Posted in Alcohol, Business, Children, Elderly, Health Bill, Healthcare, Information, Jeremy Hunt, NHS, Obesity, Patient choice, Patients, Policy, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The NHS Constitution- the turning point?

The Health and Social Care Act 2012 has always had my support. All my concerns were addressed in the final Act. The thrust of the Bill remained intact.  However, like many other people I was dismayed by the strength of … Continue reading

Posted in Andrew Lansley, Department of Health, Health Bill, Health Team, Healthcare, Hospitals, Innovation, Jeremy Hunt, NHS, Patients, Policy | Tagged , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Do private patients in the UK help or harm the NHS?

Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading

Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?

Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading

Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment